secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0001104659-22-033618
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics reports FY2021 net loss of $51.2M; cash at $291.1M
-----------------------------------------------------------------------

- Net loss of $18.4M in Q4'21 and $51.2M for FY2021, vs $8.7M and $26.5M in 2020.
- Cash and equivalents $291.1M as of Dec 31, 2021, including $190.7M net from Nov 2021 IPO.
- R&D expenses $12.4M in Q4 ($35.9M FY), up from $6.7M ($21.1M) YoY on preclinical studies.
- On track to submit IND for ENTR-601-44 (DMD exon 44) in 2H 2022.
- Appointed Jared Cohen, PhD, JD as General Counsel in January 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465922033618/0001104659-22-033618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465922033618/tm228415d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-033618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer